{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:05:34Z","timestamp":1791968734875,"version":"4.3.4"},"reference-count":146,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-026"],"award-info":[{"award-number":["2021-I2M-1-026"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.apsb.2023.02.013","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T11:47:15Z","timestamp":1677584835000},"page":"3659-3677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Research advances in peptide\u2012drug conjugates"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-099X","authenticated-orcid":false,"given":"Liming","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingji","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.02.013_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12951-021-00783-x","article-title":"pH-Responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma","volume":"19","author":"Wu","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2023.02.013_bib2","article-title":"Magnetic fluid hyperthermia based on magnetic nanoparticles: physical characteristics, historical perspective, clinical trials, technological challenges, and recent advances","volume":"3","author":"Etemadi","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.apsb.2023.02.013_bib3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.apsb.2019.08.003","article-title":"Recent progress in drug delivery","volume":"9","author":"Li","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.02.013_bib4","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1039\/c3cc43687j","article-title":"Biomimetic pseudopolyrotaxane prodrug micelles with high drug content for intracellular drug delivery","volume":"49","author":"Wang","year":"2013","journal-title":"Chem Commun"},{"key":"10.1016\/j.apsb.2023.02.013_bib5","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/ja909475m","article-title":"Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery","volume":"132","author":"Shen","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2023.02.013_bib6","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1039\/D0CS00556H","article-title":"Peptides as a platform for targeted therapeutics for cancer: peptide\u2012drug conjugates (PDCs)","volume":"50","author":"Cooper","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2023.02.013_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2015010159","article-title":"Colloidal drug delivery systems: current status and future directions","volume":"32","author":"Garg","year":"2015","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.apsb.2023.02.013_bib8","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.apsb.2021.04.001","article-title":"Oral delivery of proteins and peptides: challenges, status quo and future perspectives","volume":"11","author":"Zhu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.02.013_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2019.105567","article-title":"Bombesin receptors as potential targets for anticancer drug delivery and imaging","volume":"114","author":"Pooja","year":"2019","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2023.02.013_bib10","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3892\/mmr.2017.6419","article-title":"iRGD as a tumorpenetrating peptide for cancer therapy (Review)","volume":"15","author":"Yin","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.apsb.2023.02.013_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bip.21328","article-title":"Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials","volume":"94","author":"Cui","year":"2010","journal-title":"Biopolymers"},{"key":"10.1016\/j.apsb.2023.02.013_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-8722-5-70","article-title":"Targeted drug delivery for cancer therapy: the other side of antibodies","volume":"5","author":"Firer","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2023.02.013_bib13","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.02.013_bib14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cclet.2018.05.024","article-title":"Recent advances in enzyme-mediated peptide ligation","volume":"29","author":"Xu","year":"2018","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2023.02.013_bib15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","article-title":"Peptide\u2012drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?.","volume":"13","author":"Fu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.02.013_bib16","first-page":"92","article-title":"Multifunctional building elements for the construction of peptide drug conjugates","volume":"3","author":"Xu","year":"2022","journal-title":"Eng Regen"},{"key":"10.1016\/j.apsb.2023.02.013_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113712","article-title":"Source and exploration of the peptides used to construct peptide\u2012drug conjugates","volume":"224","author":"Zhou","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib18","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.2174\/0929867324666170404142840","article-title":"Peptide\u2012drug conjugate: a novel drug design approach","volume":"24","author":"Ma","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.apsb.2014.03.001","article-title":"Brain tumor-targeted drug delivery strategies","volume":"4","author":"Wei","year":"2014","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.02.013_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.02.013_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5381.2009.00057.x","article-title":"Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics","volume":"157","author":"Heitz","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2023.02.013_bib22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1039\/C5BM00433K","article-title":"The next generation cell-penetrating peptide and carbon dot conjugated nano-liposome for transdermal delivery of curcumin","volume":"4","author":"Patra","year":"2016","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib23","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1038\/s41598-019-40103-w","article-title":"Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin","volume":"9","author":"Ruczynski","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2023.02.013_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12951-019-0529-4","article-title":"A chitosan-based cascade-responsive drug delivery system for triple-negative breast cancer therapy","volume":"17","author":"Niu","year":"2019","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2023.02.013_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2018.09.011","article-title":"Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2","volume":"551","author":"Xiang","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2023.02.013_bib26","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41563-019-0503-4","article-title":"Furin-mediated intracellular self-assembly of olsalazine nanoparticles for enhanced magnetic resonance imaging and tumour therapy","volume":"18","author":"Yuan","year":"2019","journal-title":"Nat Mater"},{"key":"10.1016\/j.apsb.2023.02.013_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2014.11.004","article-title":"Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides","volume":"197","author":"Kamei","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.02.013_bib28","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1021\/acsami.5b04517","article-title":"Activable cell-penetrating peptide conjugated prodrug for tumor targeted drug delivery","volume":"7","author":"Cheng","year":"2015","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2023.02.013_bib29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jconrel.2020.10.063","article-title":"pH-Activatable cell penetrating peptide dimers for potent delivery of anticancer drug to triple-negative breast cancer","volume":"330","author":"Nam","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.02.013_bib30","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1002\/chem.201905159","article-title":"Cancer-cell-specific drug delivery by a tumor-homing cpp-gossypol conjugate employing a tracelessly cleavable linker","volume":"26","author":"Maity","year":"2020","journal-title":"Chemistry"},{"key":"10.1016\/j.apsb.2023.02.013_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113050","article-title":"Discovery of novel cell-penetrating and tumor-targeting peptide\u2012drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment","volume":"213","author":"Deng","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/molecules24020351","article-title":"Peptide-based drug-delivery systems in biotechnological applications: recent advances and perspectives","volume":"24","author":"Tesauro","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2023.02.013_bib33","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.drudis.2019.06.013","article-title":"The role of molecular simulations in understanding the mechanisms of cell-penetrating peptides","volume":"24","author":"Reid","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2023.02.013_bib34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol Sci"},{"issue":"Suppl 2","key":"10.1016\/j.apsb.2023.02.013_bib35","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.33549\/physiolres.933975","article-title":"Cell-penetrating peptides: a useful tool for the delivery of various cargoes into cells","volume":"67","author":"Bohmova","year":"2018","journal-title":"Physiol Res"},{"key":"10.1016\/j.apsb.2023.02.013_bib36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0092-8674(88)90263-2","article-title":"Cellular uptake of the tat protein from human immunodeficiency virus","volume":"55","author":"Frankel","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2023.02.013_bib37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0092-8674(88)90262-0","article-title":"Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein","volume":"55","author":"Green","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2023.02.013_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jconrel.2014.05.051","article-title":"Controlled release of free doxorubicin from peptide\u2012drug conjugates by drug loading","volume":"191","author":"Chen","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.02.013_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.peptides.2014.12.001","article-title":"Cell penetrating peptide TAT can kill cancer cells via membrane disruption after attachment of camptothecin","volume":"63","author":"Song","year":"2015","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2023.02.013_bib40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/DDDT.S161821","article-title":"Cell-penetrating peptide conjugates of gambogic acid enhance the antitumor effect on human bladder cancer EJ cells through ROS-mediated apoptosis","volume":"12","author":"Lyu","year":"2018","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.apsb.2023.02.013_bib41","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1021\/acs.bioconjchem.1c00123","article-title":"Penetrating the blood\u2012brain barrier with new peptide-porphyrin conjugates having anti-HIV Activity","volume":"32","author":"Mendonca","year":"2021","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib42","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/pharmaceutics14040738","article-title":"Targeting Zika virus with new brain- and placenta-crossing peptide-porphyrin conjugates","volume":"14","author":"Todorovski","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2023.02.013_bib43","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/psc.2672","article-title":"Cell penetration: scope and limitations by the application of cell-penetrating peptides","volume":"20","author":"Reissmann","year":"2014","journal-title":"J Pept Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2013.10.005","article-title":"Cyclization enhances function of linear anti-arthritic peptides","volume":"150","author":"Ali","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.apsb.2023.02.013_bib45","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1021\/acs.molpharmaceut.9b00633","article-title":"Cyclic cell-penetrating peptides as efficient intracellular drug delivery tools","volume":"16","author":"Park","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2023.02.013_bib46","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3390\/molecules24071427","article-title":"Synthesis and antiproliferative activities of conjugates of paclitaxel and camptothecin with a cyclic cell-penetrating peptide","volume":"24","author":"El-Sayed","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2023.02.013_bib47","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1021\/acs.bioconjchem.1c00319","article-title":"Targeted delivery of cabazitaxel using cyclic cell-penetrating peptide and biomarkers of extracellular matrix for prostate and breast cancer therapy","volume":"32","author":"Park","year":"2021","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib48","first-page":"149","article-title":"Targeted drug delivery systems and their therapeutic applications in cancer and immune pathological conditions","volume":"17","author":"Iqbal","year":"2017","journal-title":"Infect Disord: Drug Targets"},{"key":"10.1016\/j.apsb.2023.02.013_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121628","article-title":"Novel synovial targeting peptide-sinomenine conjugates as a potential strategy for the treatment of rheumatoid arthritis","volume":"617","author":"Zhang","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2023.02.013_bib50","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3390\/cancers14081877","article-title":"The peptide\u2012drug conjugate TH1902: a new sortilin receptor-mediated cancer therapeutic against ovarian and endometrial cancers","volume":"14","author":"Currie","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2023.02.013_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105453","article-title":"A designed cyclic peptide based on Trastuzumab used to construct peptide\u2012drug conjugates for its HER2-targeting ability","volume":"117","author":"Zhou","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib52","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/biomedicines9080849","article-title":"Development and characterization of a novel peptide\u2012drug conjugate with DM1 for treatment of FGFR2-positive tumors","volume":"9","author":"Wang","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.apsb.2023.02.013_bib53","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.3390\/cancers13153788","article-title":"Cyclic derivatives of the chemerin c-terminus as metabolically stable agonists at the chemokine-like receptor 1 for cancer treatment","volume":"13","author":"Fischer","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2023.02.013_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247045","article-title":"A \u201cligand-targeting\u201d peptide\u2012drug conjugate: targeted intracellular drug delivery by VEGF-binding helix-loop-helix peptides via receptor-mediated endocytosis","volume":"16","author":"Michigami","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2023.02.013_bib55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2017.08.040","article-title":"Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells","volume":"408","author":"Bashari","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2023.02.013_bib56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/1061186X.2015.1066794","article-title":"Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide\u2012drug conjugate via activating somatostatin receptor type II","volume":"24","author":"Sun","year":"2016","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2023.02.013_bib57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1039\/D1RA08136E","article-title":"Development of novel bone targeting peptide\u2012drug conjugate of 13-aminomethyl-15-thiomatrine for osteoporosis therapy","volume":"12","author":"Su","year":"2021","journal-title":"RSC Adv"},{"key":"10.1016\/j.apsb.2023.02.013_bib58","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molmet.2019.11.009","article-title":"NPY1R-targeted peptide-mediated delivery of a dual PPARalpha\/gamma agonist to adipocytes enhances adipogenesis and prevents diabetes progression","volume":"31","author":"Wittrisch","year":"2020","journal-title":"Mol Metabol"},{"key":"10.1016\/j.apsb.2023.02.013_bib59","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11095-019-2688-2","article-title":"Transferrin receptor targeted cellular delivery of doxorubicin via a reduction-responsive peptide\u2012drug conjugate","volume":"36","author":"Li","year":"2019","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2023.02.013_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apcsb.2014.11.001","article-title":"Protein- and peptide\u2012drug conjugates: an emerging drug delivery technology","volume":"98","author":"Vhora","year":"2015","journal-title":"Adv Protein Chem Struct Biol"},{"key":"10.1016\/j.apsb.2023.02.013_bib61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jconrel.2022.04.014","article-title":"Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC","volume":"346","author":"Kim","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.02.013_bib62","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1021\/acs.bioconjchem.9b00292","article-title":"Kiss and run: promoting effective and targeted cellular uptake of a drug delivery vehicle composed of an integrin-targeting diketopiperazine peptidomimetic and a cell-penetrating peptide","volume":"30","author":"Feni","year":"2019","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib63","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1530\/ERC-20-0442","article-title":"New drug delivery strategies targeting the GnRH receptor in breast and other cancers","volume":"28","author":"Ghaly","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.apsb.2023.02.013_bib64","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1095\/biolreprod.105.043489","article-title":"Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers","volume":"73","author":"Nagy","year":"2005","journal-title":"Biol Reprod"},{"key":"10.1016\/j.apsb.2023.02.013_bib65","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.3390\/ijms23095071","article-title":"Development and biochemical characterization of self-immolative linker containing GnRH-III-drug conjugates","volume":"23","author":"Schuster","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib66","doi-asserted-by":"crossref","first-page":"e3135","DOI":"10.1002\/psc.3135","article-title":"Synthesis, in\u00a0vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates","volume":"25","author":"Li","year":"2019","journal-title":"J Pept Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib67","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<188::AID-CNCR26>3.0.CO;2-3","article-title":"Expression of somatostatin receptors in peritumoral veins of human tumors","volume":"85","author":"Denzler","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.apsb.2023.02.013_bib68","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/bip.22694","article-title":"Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety","volume":"104","author":"Redko","year":"2015","journal-title":"Biopolymers"},{"key":"10.1016\/j.apsb.2023.02.013_bib69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1039\/D1CB00036E","article-title":"Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells","volume":"3","author":"Pryyma","year":"2022","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.apsb.2023.02.013_bib70","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1039\/C4OB00447G","article-title":"Self-assembly of peptides to nanostructures","volume":"12","author":"Mandal","year":"2014","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib71","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/ar900077c","article-title":"Stang PJ Self-organization in coordination-driven self-assembly","volume":"42","author":"Northrop","year":"2009","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.apsb.2023.02.013_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312662","article-title":"Self-assembling peptides: from design to biomedical applications","volume":"22","author":"La Manna","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib73","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1021\/acs.molpharmaceut.0c00118","article-title":"Drug-bearing peptide-based nanospheres for the inhibition of metastasis and growth of cancer","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2023.02.013_bib74","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/acsami.8b18425","article-title":"Supramolecular hydrogel based on chlorambucil and peptide drug for cancer combination therapy","volume":"11","author":"Yang","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2023.02.013_bib75","first-page":"616","article-title":"Hyperthermic treatment of malignant diseases: current status and a view toward the future","volume":"24","author":"Dewhirst","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.apsb.2023.02.013_bib76","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/bip.21327","article-title":"Elastin-like polypeptides: biomedical applications of tunable biopolymers","volume":"94","author":"MacEwan","year":"2010","journal-title":"Biopolymers"},{"key":"10.1016\/j.apsb.2023.02.013_bib77","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1021\/acs.biomac.5b01235","article-title":"LCST Behavior is manifested in a single molecule: elastin-like polypeptide (VPGVG)n","volume":"17","author":"Zhao","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.apsb.2023.02.013_bib78","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jconrel.2020.08.065","article-title":"Temperature-triggered micellization of interferon alpha-diblock copolypeptide conjugate with enhanced stability and pharmacology","volume":"328","author":"Wang","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.02.013_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202100081","article-title":"Self-assembly or coassembly of multiresponsive histidine-containing elastin-like polypeptide block copolymers","volume":"21","author":"Abdelghani","year":"2021","journal-title":"Macromol Biosci"},{"key":"10.1016\/j.apsb.2023.02.013_bib80","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.3390\/ijms21197229","article-title":"Differential effect of extracellular acidic environment on il-1\u03b2 released from human and mouse phagocytes","volume":"21","author":"Susjan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib81","first-page":"1734","article-title":"A smart tumor targeting peptide\u2012drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7\/Adr cells","volume":"23","author":"Song","year":"2016","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2023.02.013_bib82","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1021\/acs.molpharmaceut.6b00847","article-title":"Therapeutic efficacy of a family of pHLIP-MMAF conjugates in cancer cells and mouse models","volume":"14","author":"Burns","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2023.02.013_bib83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/bse0380021","article-title":"Matrix metalloproteinases in cancer","volume":"38","author":"Itoh","year":"2002","journal-title":"Essays Biochem"},{"key":"10.1016\/j.apsb.2023.02.013_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201700867","article-title":"Drug-bearing supramolecular MMP inhibitor nanofibers for inhibition of metastasis and growth of liver cancer","volume":"5","author":"Ji","year":"2018","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib85","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.biomaterials.2018.08.026","article-title":"Tumor-triggered transformation of chimeric peptide for dual-stage-amplified magnetic resonance imaging and precise photodynamic therapy","volume":"182","author":"Zhang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2023.02.013_bib86","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/acs.jmedchem.0c01530","article-title":"Peptide\u2013drug conjugates with different linkers for cancer therapy","volume":"64","author":"Alas","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib87","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/psc.2753","article-title":"Drug delivery and release systems for targeted tumor therapy","volume":"21","author":"Bohme","year":"2015","journal-title":"J Pept Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib88","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.3390\/ijms20194763","article-title":"Improved in\u00a0vivo anti-tumor and anti-metastatic effect of GnRH-III-Daunorubicin analogs on colorectal and breast carcinoma bearing mice","volume":"20","author":"Randelovic","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/pharmaceutics10040223","article-title":"Enhanced in\u00a0vitro antitumor activity of GnRH-III-Daunorubicin bioconjugates influenced by sequence modification","volume":"10","author":"Schuster","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2023.02.013_bib90","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jconrel.2018.01.033","article-title":"A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers","volume":"275","author":"Liang","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.02.013_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178632","article-title":"NGR-peptide\u2012drug conjugates with dual targeting properties","volume":"12","author":"Enyedi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2023.02.013_bib92","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3390\/pharmaceutics13050661","article-title":"Evaluation of a keratin 1 targeting peptide-doxorubicin conjugate in a mouse model of triple-negative breast cancer","volume":"13","author":"Saghaeidehkordi","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2023.02.013_bib93","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.3390\/ijms20133291","article-title":"EDB-FN targeted peptide\u2012drug conjugates for use against prostate cancer","volume":"20","author":"Park","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib94","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1021\/jm001065f","article-title":"Novel peptide conjugates for tumor-specific chemotherapy","volume":"44","author":"Langer","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib95","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/acs.jmedchem.0c01387","article-title":"Novel N-methylated cyclodepsipeptide prodrugs for targeted cancer therapy","volume":"64","author":"Wu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib96","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.7150\/thno.20242","article-title":"A nanosystem of amphiphilic oligopeptide\u2012drug conjugate actualizing both avb3 targeting and reduction-triggered release for maytansinoid","volume":"7","author":"Liang","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2023.02.013_bib97","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1021\/acs.jmedchem.6b00043","article-title":"Double methotrexate-modified neuropeptide y analogues express increased toxicity and overcome drug resistance in breast cancer cells","volume":"59","author":"Bohme","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113018","article-title":"Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable \"click\" oxime bond tethers and preclinical evaluation against prostate cancer","volume":"211","author":"Vrettos","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib99","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/bip.22800","article-title":"Dual-drug RGD conjugates provide enhanced cytotoxicity to melanoma and non-small lung cancer cells","volume":"106","author":"Gilad","year":"2016","journal-title":"Biopolymers"},{"key":"10.1016\/j.apsb.2023.02.013_bib100","doi-asserted-by":"crossref","first-page":"41889","DOI":"10.1021\/acsami.9b14046","article-title":"Blood\u2012brain barrier- and blood\u2012brain tumor barrier-penetrating peptide-derived targeted therapeutics for glioma and malignant tumor brain metastases","volume":"11","author":"Chen","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2023.02.013_bib101","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejmech.2019.01.041","article-title":"Development of bioactive gemcitabine-D-Lys(6)-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile","volume":"166","author":"Sayyad","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib102","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1002\/anie.201603488","article-title":"Integrin-targeting knottin peptide\u2012drug conjugates are potent inhibitors of tumor cell proliferation","volume":"55","author":"Cox","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.02.013_bib103","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1039\/D0SM00428F","article-title":"Amphiphilic drug-peptide-polymer conjugates based on poly(ethylene glycol) and hyperbranched polyglycerol for epidermal growth factor receptor targeting: the effect of conjugate aggregation on in\u00a0vitro activity","volume":"16","author":"Petho","year":"2020","journal-title":"Soft Matter"},{"key":"10.1016\/j.apsb.2023.02.013_bib104","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.bcp.2006.10.028","article-title":"Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin","volume":"73","author":"Bidwell","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2023.02.013_bib105","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/nm.3009","article-title":"Targeted estrogen delivery reverses the metabolic syndrome","volume":"18","author":"Finan","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2023.02.013_bib106","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/psc.2617","article-title":"Novel cleavable cell-penetrating peptide\u2012drug conjugates: synthesis and characterization","volume":"20","author":"Lelle","year":"2014","journal-title":"J Pept Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib107","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2023.02.013_bib108","doi-asserted-by":"crossref","first-page":"8214","DOI":"10.1002\/anie.201002639","article-title":"Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics","volume":"49","author":"Lee","year":"2010","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.02.013_bib109","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1021\/bc049853x","article-title":"Acetals as pH-sensitive linkages for drug delivery","volume":"15","author":"Gillies","year":"2004","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib110","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1039\/C9TB00651F","article-title":"Transferrin receptor-targeted redox\/pH-sensitive podophyllotoxin prodrug micelles for multidrug-resistant breast cancer therapy","volume":"7","author":"Li","year":"2019","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2023.02.013_bib111","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1021\/jm501371s","article-title":"Organic carbamates in drug design and medicinal chemistry","volume":"58","author":"Ghosh","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib112","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1016\/j.bmcl.2018.07.030","article-title":"Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug","volume":"28","author":"Thiele","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2023.02.013_bib113","doi-asserted-by":"crossref","DOI":"10.1038\/srep15216","article-title":"Amino acid carbamates as prodrugs of resveratrol","volume":"5","author":"Mattarei","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2023.02.013_bib114","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/1873-3468.13250","article-title":"Probing the interaction of a quercetin bioconjugate with Bcl-2 in living human cancer cells with in-cell NMR spectroscopy","volume":"592","author":"Primikyri","year":"2018","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2023.02.013_bib115","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1002\/anie.200501428","article-title":"Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin\u2014proteasome system, and onto human diseases and drug targeting (nobel lecture)","volume":"44","author":"Ciechanover","year":"2005","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.02.013_bib116","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.critrevonc.2003.09.001","article-title":"The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia","volume":"50","author":"Klein","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.apsb.2023.02.013_bib117","doi-asserted-by":"crossref","first-page":"52230","DOI":"10.18632\/oncotarget.10735","article-title":"Controlled release strategy of paclitaxel by conjugating to matrix metalloproteinases-2 sensitive peptide","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2023.02.013_bib118","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2023.02.013_bib119","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lfs.2018.03.023","article-title":"Toxicity of Doxorubicin (Dox) to different experimental organ systems","volume":"200","author":"Pugazhendhi","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib120","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1021\/acs.bioconjchem.9b00755","article-title":"Targeting triple negative breast cancer cells with novel cytotoxic peptide-doxorubicin conjugates","volume":"30","author":"Ziaei","year":"2019","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib121","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/bc300585h","article-title":"Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site","volume":"24","author":"Zhang","year":"2013","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib122","first-page":"888","article-title":"A case of secondary sclerosing cholangitis caused by chemotherapy with nab-paclitaxel","volume":"112","author":"Matsuo","year":"2015","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.apsb.2023.02.013_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202001960","article-title":"Improved Antiglioblastoma activity and bbb permeability by conjugation of paclitaxel to a cell-penetrative MMP-2-cleavable peptide","volume":"8","author":"Hua","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2023.02.013_bib124","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1007\/s11095-010-0235-2","article-title":"Multifunctional tumor-targeted polymer-peptide\u2012drug delivery system for treatment of primary and metastatic cancers","volume":"27","author":"Chandna","year":"2010","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2023.02.013_bib125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-3109(00)00189-2","article-title":"Mechanisms of action of methotrexate","volume":"47","author":"Genestier","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.apsb.2023.02.013_bib126","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.npep.2015.11.019","article-title":"Controlling toxicity of NPY-drug conjugates by different chemical linker structures","volume":"55","author":"B\u00f6hme","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.apsb.2023.02.013_bib127","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.bioconjchem.7b00421","article-title":"Multifunctional avb6 integrin-specific peptide-Pt(IV) conjugates for cancer cell targeting","volume":"28","author":"Conibear","year":"2017","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2174\/1389200211314060004","article-title":"Prodrug design targeting intestinal PepT1 for improved oral absorption: design and performance","volume":"14","author":"Zhang","year":"2013","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.apsb.2023.02.013_bib129","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/mp800200a","article-title":"Synthesis, transport and pharmacokinetics of 5\u2032-amino acid ester prodrugs of 1-beta-d-arabinofuranosylcytosine","volume":"6","author":"Sun","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2023.02.013_bib130","doi-asserted-by":"crossref","first-page":"1133-e112","DOI":"10.1634\/theoncologist.2018-0292","article-title":"NGR-hTNF and doxorubicin as second-line treatment of patients with small cell lung cancer","volume":"23","author":"Gregorc","year":"2018","journal-title":"Oncol"},{"key":"10.1016\/j.apsb.2023.02.013_bib131","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/art.21827","article-title":"Formatted anti\u2013tumor necrosis factor \u03b1 VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis","volume":"54","author":"Coppieters","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.apsb.2023.02.013_bib132","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1467-7652.2010.00523.x","article-title":"ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock","volume":"9","author":"Conrad","year":"2011","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.apsb.2023.02.013_bib133","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","article-title":"Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities","volume":"6","author":"Jonasch","year":"2001","journal-title":"Oncol"},{"key":"10.1016\/j.apsb.2023.02.013_bib134","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10616-014-9743-y","article-title":"Recombinant IFN-a2a-NGR exhibits higher inhibitory function on tumor neovessels formation compared with IFN-a2a in\u00a0vivo and in\u00a0vitro","volume":"67","author":"Li","year":"2015","journal-title":"Cytotechnology"},{"key":"10.1016\/j.apsb.2023.02.013_bib135","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1021\/acs.molpharmaceut.8b00498","article-title":"Cyclic RGD-peptide-functionalized polylipopeptide micelles for enhanced loading and targeted delivery of monomethyl auristatin E","volume":"15","author":"Qiu","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2023.02.013_bib136","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2013.05.031","article-title":"Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan","volume":"170","author":"Ahn","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2023.02.013_bib137","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/pharmaceutics12020122","article-title":"Biological evaluation of naproxen-dehydrodipeptide conjugates with self-hydrogelation capacity as dual LOX\/COX inhibitors","volume":"12","author":"Moreira","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2023.02.013_bib138","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/pharmaceutics14040693","article-title":"New peptide based fluconazole conjugates with expanded molecular targets","volume":"14","author":"Brankiewicz","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2023.02.013_bib139","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejpb.2019.06.002","article-title":"Imine bond formation: a novel concept to incorporate peptide drugs in self-emulsifying drug delivery systems (SEDDS)","volume":"142","author":"Dizdarevic","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2023.02.013_bib140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1124\/jpet.119.263566","article-title":"Use of a noninvasive brain-penetrating peptide\u2012drug conjugate strategy to improve the delivery of opioid pain relief medications to the brain","volume":"374","author":"Eiselt","year":"2020","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2023.02.013_bib141","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.3390\/molecules24244559","article-title":"Coupling the antimalarial cell penetrating peptide TP10 to classical antimalarial drugs primaquine and chloroquine produces strongly hemolytic conjugates","volume":"24","author":"Aguiar","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2023.02.013_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112389","article-title":"Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents","volume":"198","author":"Han","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.02.013_bib143","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the First FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2023.02.013_bib144","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3390\/jcm9103120","article-title":"Melflufen: a peptide\u2012drug conjugate for the treatment of multiple myeloma","volume":"9","author":"Mateos","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.apsb.2023.02.013_bib145","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2011.427","article-title":"Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1","volume":"105","author":"Bertrand","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2023.02.013_bib146","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide\u2012drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:02:23Z","timestamp":1761930143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383523000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":146,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2211383523000606"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.02.013","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research advances in peptide\u2012drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}